Xpovio (Selinexor)
- Medicine Name: Aduhelm
- Generic Name: Aducanumab-avwa
- Dosage Form & Strength: Injection: 170 mg/1.7 mL (100 mg/mL) and 300 mg/3 mL (100 mg/mL) in a single-dose vial
- Manufactured By: Biogen Inc.
Xpovio first-in-class oral selective inhibitor of nuclear export (SINE) used:
In combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy.
In combination with dexamethasone for the treat adult patients with relapsed or refractory multiple myeloma who have received a least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody.
For the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBC) not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Recommended Dosage:
Multiple Myeloma: In Combination with Bortezomib and Dexamethasone (SVd): The recommended dosage of xpovio tablets is 10 mg taken orally once weekly on Day 1 of each week until disease progression or unacceptable toxicity in combination with:
Bortezomib 1.3 mg/m2 is administered subcutaneously once weekly on Day 1 of each weeks for 4 weeks followed by 1 week off.
Dexamethasone 20 mg taken orally twice weekly on Days 1 and 2 of each week.
In Combination with Dexamethasone (Sd): The recommended dosage of XPOVIO is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity in combination with dexamethasone 20 mg taken orally with each dose of XPOVIO on Days 1 and 3 of each week.
Diffuse Large B‐Cell Lymphoma: The recommended dosage of XPOVIO is 60 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.
- The selinexor multiple myeloma medicine can cause life‐threatening thrombocytopenia, potentially leading to hemorrhage. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first three months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly.
- XPOVIO can cause life‐threatening neutropenia, potentially increasing the risk of infection. Obtain white blood cell counts with differential at baseline and throughout treatment. Monitor more frequently during the first three months of treatment. Monitor patients for signs and symptoms of concomitant infection and evaluate promptly.
- XPOVIO can cause severe or life‐threatening hyponatremia. Monitor sodium level at baseline and throughout treatment. Monitor more frequently during the first two months of treatment. Correct sodium levels for concurrent hyperglycemia (serum glucose >150 mg/dL) and high serum paraprotein levels.
- XPOVIO can cause serious and fatal infections. Most of these infections were not associated with Grade 3 or higher neutropenia. Atypical infections reported after XPOVIO includebut are not limited to, fungal pneumonia and herpesvirus infection. Monitor for signs and symptoms of infection, evaluate and treat promptly.
- The xpovio multiple myeloma medicine can cause life‐threatening neurological toxicities.Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, until the neurological toxicity fully resolves. Optimize hydration status, hemoglobin level, and concomitant medications to avoid exacerbating dizziness or mental status changes.
- XPOVIO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.
What documents are required to import XPOVIO to India?
XPOVIO (selinexor) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
- The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is XPOVIO available in India?
XPOVIO (selinexor tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
XPOVIO can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of XPOVIO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Xpovio 20 mg tablets price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
What is the Generic Name for the trade name drug Xpovio®?
Selinexor is Generic Name for the trade name drug Xpovio®.
What is the Manufacturer Name of Xpovio®?
Xpovio® is manufactured by Karyopharm Therapeutics Inc.
Is Xpovio® approved by the FDA?
Yes, Xpovio® was first approved by the FDA. Date of approval: July 3, 2019.
What is the dosage and form of Xpovio® supplied?
Xpovio® is supplied as Tablets: 20 mg for oral administration.
What are the most common side effects due to Xpovio®?
MM: (in combination with SVd): nausea, fatigue, upper respiratory tract infection, decreased appetite, diarrhea, decreased weight, peripheral neuropathy and vomiting.
MM: (in combination with Sd): fatigue, nausea, anemia, thrombocytopenia, decreased appetite, decreased weight, diarrhea, constipation, upper respiratory tract infection, neutropenia and leukopenia.
DLBCL: fatigue, nausea, constipation, weight decrease, appetite decrease, vomiting, diarrhea and pyrexia.
How much does Selinexor cost in India?
The selinexor cost in India is very reasonable. In order to procure this RRMM medication authentically, you can call or WhatsApp +91-9310090915 or send mail to E-mail: info@indianpharmanetwork.in.
What are the storage conditions of Xpovio®?
Store at or below 86°F (30°C). It comes in a child-resistant blister pack. Keep it and all medicines out of the reach of children.
Is it safe to buy Xpovio® online in India?
Yes, You can buy Xpovio online at the best price in India authentically from https://www.indianpharmanetwork.in/ if Xpovio has not been approved or is not available in your home country.
Is Indian Pharma Network certified by WHO-GDP & ISO 9001:2008 authorities?
Yes, We are certified from the top-most authorities like WHO-GDP & ISO 9001:2008. We are legitimate and most authentic Wholesalers and Suppliers of Xpovio in India. We can help you to get this medicine at the lowest affordable prices.
What are the Highlights of prescribing information for Xpovio®?
Click Here to download full Xpovio prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.